These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 31867773)

  • 1. Decision-making regarding primary prevention implantable cardioverter-defibrillators among older adults.
    Hess PL; Matlock DD; Al-Khatib SM
    Clin Cardiol; 2020 Feb; 43(2):187-195. PubMed ID: 31867773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Effectiveness of Primary Prevention Implantable Cardioverter-Defibrillators in Older Heart Failure Patients With Diabetes Mellitus.
    Sharma A; Wu J; Xu H; Hernandez A; Felker GM; Al-Khatib S; Green J; Matsouaka R; Fonarow GC; Singh JP; Heidenreich PA; Ezekowitz JA; DeVore A
    J Am Heart Assoc; 2020 Jun; 9(12):e012405. PubMed ID: 32476539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapy optimization in patients with heart failure: the role of the wearable cardioverter-defibrillator in a real-world setting.
    Röger S; Rosenkaimer SL; Hohneck A; Lang S; El-Battrawy I; Rudic B; Tülümen E; Stach K; Kuschyk J; Akin I; Borggrefe M
    BMC Cardiovasc Disord; 2018 Mar; 18(1):52. PubMed ID: 29544442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kidney function and appropriateness of device therapies in adults with implantable cardioverter defibrillators.
    Bansal N; Szpiro A; Masoudi F; Greenlee RT; Smith DH; Magid DJ; Gurwitz JH; Reynolds K; Tabada GH; Sung SH; Dighe A; Cassidy-Bushrow A; Garcia-Montilla R; Hammill S; Hayes J; Kadish A; Sharma P; Varosy P; Vidaillet H; Go AS
    Heart; 2017 Apr; 103(7):529-537. PubMed ID: 27742796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes After Implantable Cardioverter-Defibrillator Generator Replacement for Primary Prevention of Sudden Cardiac Death.
    Madhavan M; Waks JW; Friedman PA; Kramer DB; Buxton AE; Noseworthy PA; Mehta RA; Hodge DO; Higgins AY; Webster TL; Witt CM; Cha YM; Gersh BJ
    Circ Arrhythm Electrophysiol; 2016 Mar; 9(3):e003283. PubMed ID: 26921377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Joint Shock/Death Risk Prediction Model for Patients Considering Implantable Cardioverter-Defibrillators.
    Reeder HT; Shen C; Buxton AE; Haneuse SJ; Kramer DB
    Circ Cardiovasc Qual Outcomes; 2019 Aug; 12(8):e005675. PubMed ID: 31412732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deactivation of implantable cardioverter-defibrillators: results of patient surveys.
    Herman D; Stros P; Curila K; Kebza V; Osmancik P
    Europace; 2013 Jul; 15(7):963-9. PubMed ID: 23447573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association Between Comorbidities and Outcomes in Heart Failure Patients With and Without an Implantable Cardioverter-Defibrillator for Primary Prevention.
    Khazanie P; Hellkamp AS; Fonarow GC; Bhatt DL; Masoudi FA; Anstrom KJ; Heidenreich PA; Yancy CW; Curtis LH; Hernandez AF; Peterson ED; Al-Khatib SM
    J Am Heart Assoc; 2015 Aug; 4(8):e002061. PubMed ID: 26251283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application and comparison of the FADES, MADIT, and SHFM-D risk models for risk stratification of prophylactic implantable cardioverter-defibrillator treatment.
    van der Heijden AC; van Rees JB; Levy WC; van der Bom JG; Cannegieter SC; de Bie MK; van Erven L; Schalij MJ; Borleffs CJ
    Europace; 2017 Jan; 19(1):72-80. PubMed ID: 28130376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assisting Black Patients With Decision-Making for Implantable Cardioverter Defibrillator Therapy: Qualitative Findings From the Videos to Reduce Racial Disparities in ICD Therapy via Innovative Designs (VIVID) Trial.
    Jackson LR; McKenna K; Corneli A; Dombeck C; Brelsford K; Thomas KL
    Circ Cardiovasc Qual Outcomes; 2024 Jul; 17(7):e010550. PubMed ID: 38864226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylactic implantable cardioverter defibrillators for primary prevention: From implantation to heart transplantation.
    Algalarrondo V; Perault R; Bories MC; Narayanan K; Garcia R; Combes N; Perier MC; Defaye P; Sadoul N; Gras D; Klug D; Bordachar P; Fauchier L; Deharo JC; Leclercq C; Boveda S; Marijon E; Babuty D;
    Arch Cardiovasc Dis; 2018 Dec; 111(12):758-765. PubMed ID: 30078651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival after primary prevention implantable cardioverter-defibrillator placement among patients with chronic kidney disease.
    Hess PL; Hellkamp AS; Peterson ED; Sanders GD; Al-Khalidi HR; Curtis LH; Hammill BG; Pun PH; Curtis JP; Anstrom KJ; Hammill SC; Al-Khatib SM
    Circ Arrhythm Electrophysiol; 2014 Oct; 7(5):793-9. PubMed ID: 25038119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disrupting the Approach to Sudden Cardiac Death: From Vulnerable Ejection Fraction to Vulnerable Patient.
    Chugh SS
    Circulation; 2018 Jan; 137(1):7-9. PubMed ID: 29279335
    [No Abstract]   [Full Text] [Related]  

  • 14. Protein biomarkers identify patients unlikely to benefit from primary prevention implantable cardioverter defibrillators: findings from the Prospective Observational Study of Implantable Cardioverter Defibrillators (PROSE-ICD).
    Cheng A; Zhang Y; Blasco-Colmenares E; Dalal D; Butcher B; Norgard S; Eldadah Z; Ellenbogen KA; Dickfeld T; Spragg DD; Marine JE; Guallar E; Tomaselli GF
    Circ Arrhythm Electrophysiol; 2014 Dec; 7(6):1084-91. PubMed ID: 25273351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The implantable cardioverter-defibrillator: An update.
    Miller JD; Yousuf O; Berger RD
    Trends Cardiovasc Med; 2015 Oct; 25(7):606-11. PubMed ID: 25912255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual- vs. single-chamber defibrillators for primary prevention of sudden cardiac death: long-term follow-up of the Défibrillateur Automatique Implantable-Prévention Primaire registry.
    Defaye P; Boveda S; Klug D; Beganton F; Piot O; Narayanan K; Périer MC; Gras D; Fauchier L; Bordachar P; Algalarrondo V; Babuty D; Deharo JC; Leclercq C; Marijon E; Sadoul N;
    Europace; 2017 Sep; 19(9):1478-1484. PubMed ID: 28340096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prophylactic implantable cardioverter defibrillator treatment in patients with end-stage heart failure awaiting heart transplantation.
    Fröhlich GM; Holzmeister J; Hübler M; Hübler S; Wolfrum M; Enseleit F; Seifert B; Hürlimann D; Lehmkuhl HB; Noll G; Steffel J; Falk V; Lüscher TF; Hetzer R; Ruschitzka F
    Heart; 2013 Aug; 99(16):1158-65. PubMed ID: 23813845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implantable cardioverter defibrillator for primary prevention in patients with severe ventricular dysfunction awaiting heart transplantation.
    Cantero-Pérez EM; Sobrino-Márquez JM; Grande-Trillo A; Lage-Gallé E; Rangel-Sousa D; Esteve-Ruiz IM; Martínez-Martínez A
    Transplant Proc; 2013; 45(10):3659-61. PubMed ID: 24314988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Shared Decision-Making About End-of-Life Care Scenarios Compared Among Implantable Cardioverter Defibrillator Patients: A National Cohort Study.
    Thompson JH; Thylén I; Moser DK
    Circ Heart Fail; 2019 Oct; 12(10):e005619. PubMed ID: 31601115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time dependence of risks and benefits in pediatric primary prevention implantable cardioverter-defibrillator therapy.
    DeWitt ES; Triedman JK; Cecchin F; Mah DY; Abrams DJ; Walsh EP; Gauvreau K; Alexander ME
    Circ Arrhythm Electrophysiol; 2014 Dec; 7(6):1057-63. PubMed ID: 25262116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.